Research
Topics:
INDEX
AI-chat 3
MCS 1
PRIME 28
PRIO 3
aging 7
brain 9
brainwave 1
cancer 8
climate 3
cognition 4
covid-19 2
crime 5
culture 3
dental 1
diabetes 3
drugs 2
economy 2
energy 3
exercise 1
eyes 5
gender 1
genetics 5
gut 1
heart 2
immune 5
language 1
metabolism 1
microbiome 2
nutrition 5
obesity 1
pain 1
physical 1
politics 8
population 6
practice 1
psychology 1
quantum 1
reproduction 1
rights 1
sleep 2
tech 1
vaccine 2
war-confl
war-cyber 1
 
Scanned: 3298
Evaluated: 234
Selected: 59

 
Back Issue Map
    DIABETES    DRUGS    OBESITY   

Mdb42-002

Linafexor, a Pulsatile FXR Agonist, Augments Low-Dose Semaglutide for Weight Loss in Adults with Obesity, MASH, and Type 2 Diabetes

Quote: Thus, in a population with blunted GLP-1 responses, adding linafexor to low-dose semaglutide enhanced weight loss and improved body composition and hepatic measures while preserving tolerability--a dose-sparing, mechanism-complementary strategy (ClinicalTrials.gov number, NCT06492330).
Abstract: https://www.medrxiv.org/content/10.64898/2026.10.18.26365821v1
Full Text: https://www.medrxiv.org/content/10.64898/2026.10.18.26365821v1.full-text
Search Similar: Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho 
Search Authors: Yifei Zhang Yufei Chen Shan Huang Lei Jiang Yufan Wang Jing Ma Rong Deng Juan Du Lili Xia Yuhang Ma Peihong Wu Weituo Zhang Cong Liu Guanguan Zhao Gaihong Wang Mengyi Qian Huimin Lin Fuhua Yan Guang Ning H. Eric Xu Weiqing Wang, 

  Javilk's Research Links Newsletter for Week 42
Updated 10/24/2026-02:39:34 AM
Back Issue Topic Map
What interests you? What have you found? Tell me!
Drop me a note at Javilk.com to subscribe or submit something.